Generate a tailored SOP for Dr. Raymond Reilly. Improve your application with a focused, well-structured draft.
Raymond Reilly’s research focuses on developing novel radiopharmaceutical agents to detect and treat cancer. His work involves discovery, preclinical development, and clinical translation of agents for molecular imaging and molecularly targeted radiotherapy in cancer treatment. Recognizing cancer's complexity due to genetic variability among tumors, his laboratory employs a technique called molecular imaging, which uses probe molecules tagged with radioactive isotopes to analyze tumor characteristics through imaging technologies like single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Prof. Reilly’s team focuses on creating innovative radiopharmaceutical probes that target overexpressed proteins in tumor cells to enhance cancer diagnosis and treatment. Their unique methodologies, including the use of monoclonal antibodies and radiolabelled gold nanoparticles, aim to deliver localized radiation directly to tumor cells while minimizing damage to healthy tissues. This advanced approach has led to the development of agents entering Phase 1 clinical trials, underscoring the potential for improved oncological outcomes and personalized treatment strategies based on individual tumor profiles. Moreover, his research emphasizes the theranostic strategy, wherein agents serve dual roles in diagnosis and treatment, enhancing clinical efficacy through personalized medicine practices.
Leslie Dan Faculty of Pharmacy, University of Toronto • Toronto, ON, Canada
Leading research in radiopharmaceuticals and molecular imaging for cancer therapy.
Department of Sociology